Monoclonal antibodies (mAbs) may directly stall or kill tumour cells by binding tumour cell-specific antigens, or indirectly kill tumour cells by inhibiting the immune checkpoint molecules that ...

Indeed, most monoclonal antibody (mAb) drug discovery projects in I-O are focused on just a few targets, such as the checkpoint molecule programmed cell death 1 and CD19-specific chimeric antigen ...